Ahmed Abdalbagi: Aspirin vs Plavix – Updated Clinical and Pharmacological Breakdown
Ahmed Abdalbagi, SCFHS-Licensed Pharmacist, shared a post on LinkedIn:
“Aspirin vs. Plavix: Updated clinical and pharmacological breakdown:
Drug class and mechanism:
- Aspirin (acetylsalicylic acid):
Irreversible cox-1 inhibitor |Antiplatelet + NSAID (anti-inflammatory, analgesic, antipyretic). - Plavix (clopidogrel):
Irreversible P2Y12 ADP-receptor inhibitor | Pure antiplatelet – NO NSAID effects. - Available strengths:
Aspirin: 75mg, 81mg, 100mg, 300mg (varies by indication). Plavix: 75mg (maintenance), 300mg (loading dose).
Key contraindications:
Aspirin: Active peptic ulcer, NSAID-sensitive asthma, bleeding disorders, severe renal/hepatic impairment.
Plavix: Active bleeding, intracranial hemorrhage, hypersensitivity – safe in asthma.
Shared contraindication:
ITP (immune thrombocytopenia) – high bleeding risk.
Critical drug interaction alert – updated guidelines:
Plavix + PPIs: Significant interaction via CYP2C19 inhibition – reduces clopidogrel antiplatelet efficacy.
Avoid: Omeprazole, Esomeprazole.
Preferred PPI if mandatory: Pantoprazole (minimal CYP2C19 effect).
2024 recommendation: Use H2 blockers (e.g., famotidine) or PPI only if strongly indicated.
Primary indications – secondary prevention:
Acute Coronary Syndrome (ACS), MI, Ischemic Stroke, Post-PCI/Stent, Post-CABG.
DAPT (Dual Antiplatelet Therapy): Aspirin + Clopidogrel – duration individualized per bleeding/thrombosis risk.
DAPT Duration Post-PCI: Short-term (3-6 months) for high bleeding risk; extended if high thrombotic risk.
Genetic testing: CYP2C19 loss-of-function alleles – consider for clopidogrel non-responders.
Primary prevention: Aspirin reserved for select high CV risk patients (no routine use).
For all healthcare professionals:
Guidelines align with ACC/AHA and ESC – emphasize personalized antiplatelet therapy.
Hospital and community pharmacists: Screen for ppi interactions, educate on adherence, monitor bleeding signs.
Are you updating your DAPT protocols based on latest guidelines? How do you manage PPI interactions in practice? Tag a colleague who needs to see this.”
Stay updated on all scientific advances with Hemostasis Today.
-
May 7, 2026, 17:56The Latest Clinical Data Shaping The Evolving Landscape of Hemophilia Treatment – EAHAD
-
May 7, 2026, 17:31Talha Badar: New Classical Hematology Chapter on Bleeding and Thrombosis
-
May 7, 2026, 17:26Maria Τektonidou: Gene Network Analysis Identifies STAT1 in Thrombotic APS
-
May 7, 2026, 17:23Sonu Bhaskar: Inflammatory Biomarkers in Acute Cerebral Venous Sinus Thrombosis
-
May 7, 2026, 16:53Patricio S. Espinosa: Anticoagulation Is Not an Absolute Contraindication to Amyloid Therapy
-
May 7, 2026, 16:34Arun V J: Give Blood and Be the Hero You Always Wanted to Be
-
May 7, 2026, 16:15August Bones: When Would You Consider Placing an Inferior Vena Cava Filter After a Pulmonary Embolism?
-
May 7, 2026, 15:58Stop Asking Doctors to Do More – Reimagining the Care Team – The US Oncology
-
May 7, 2026, 15:42Chokri Ben Lamine: CVC-Associated UE-DVT and Catheter Removal